Aug 5, 2026 07:00AM
Jul 23, 2026 04:06PM
Jul 23, 2026 04:05PM
Jul 22, 2026 04:30PM
Jul 22, 2026 04:30PM
Jul 22, 2026 06:30AM
Jul 22, 2026 06:30AM Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Jul 16, 2026 08:00AM
Jul 14, 2026 07:00AM
Jul 14, 2026 07:00AM
Jun 4, 2026 04:30PM
Jun 1, 2026 02:53AM
May 31, 2026 09:06AM
May 30, 2026 08:00AM Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
Apr 30, 2026 04:32PM
Mar 27, 2026 08:16AM
Mar 27, 2026 08:15AM
Feb 26, 2026 06:45PM
Feb 23, 2026 04:05PM
Feb 17, 2026 05:05PM
Jan 30, 2026 04:30PM Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 29, 2026 07:30AM
Jan 29, 2026 07:30AM
Jan 12, 2026 06:15AM
Jan 12, 2026 06:15AM
Jan 12, 2026 06:01AM
Jan 12, 2026 06:00AM
Jan 9, 2026 08:16PM Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 6, 2026 07:30AM
Dec 5, 2025 04:30PM
Nov 7, 2025 09:02AM
Nov 7, 2025 09:00AM
Nov 4, 2025 07:00AM
Oct 31, 2025 07:00AM
Oct 31, 2025 07:00AM Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Oct 22, 2025 08:00AM
Oct 22, 2025 08:00AM
Oct 20, 2025 06:45AM
Oct 20, 2025 06:45AM
Oct 19, 2025 10:30AM
Oct 17, 2025 07:00AM
Oct 17, 2025 07:00AM Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
Oct 15, 2025 07:00AM
Sep 24, 2025 04:30PM
Sep 24, 2025 07:00AM
Sep 24, 2025 07:00AM
Sep 7, 2025 03:30AM
Sep 3, 2025 07:00AM
Aug 14, 2025 07:00AM Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025
Aug 11, 2025 05:03PM

13,200 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All